Pregnant women who receive the maternal RSV vaccine reduce their infants’ risk of hospitalization from respiratory syncytial virus by over 80% during the first six months of life, according to a major UK Health Security Agency study presented at ESCMID Global 2026. This real-world evidence confirms clinical trial findings and supports ongoing efforts to protect newborns from a leading cause of infant respiratory illness worldwide.
In Plain English: The Clinical Takeaway
- The RSV vaccine given during pregnancy passes protective antibodies to the baby, significantly lowering their chance of severe lung infection requiring hospital care.
- Protection is strongest in the first months after birth when infants are most vulnerable to RSV complications like bronchiolitis and pneumonia.
- No safety concerns were identified in the study, reinforcing the vaccine’s role as a safe preventive measure in prenatal care.
How Maternal Immunity Transfers Protection Against RSV
Respiratory syncytial virus (RSV) is a common pathogen that infects the respiratory tract, particularly dangerous in infants under six months due to their immature immune systems and small airways. When a pregnant person receives the RSV vaccine, their body produces immunoglobulin G (IgG) antibodies specific to the RSV fusion protein. These antibodies cross the placenta via the neonatal Fc receptor (FcRn), providing passive immunity to the fetus. This mechanism, known as transplacental antibody transfer, equips the newborn with immediate defense against RSV upon birth, bridging the gap until their own immune system can respond effectively.
The vaccine in question, RSVpreF (marketed as Abrysvo by Pfizer), is a bivalent recombinant protein vaccine stabilized in its prefusion conformation. It targets the RSV F glycoprotein, which the virus uses to fuse with and enter human respiratory cells. By eliciting antibodies that neutralize this fusion mechanism, the vaccine prevents viral entry and replication. Clinical trials demonstrated that maternal vaccination reduces the risk of severe RSV-associated lower respiratory tract infection in infants by approximately 82% within the first 90 days of life, with sustained efficacy through six months.
Real-World Impact: UKHSA Data Confirms Clinical Trial Efficacy
The UK Health Security Agency (UKHSA) study analyzed national immunization and hospital admission records from September 2024 to February 2026, covering over 450,000 pregnancies in England. Infants born to vaccinated mothers showed an 81% reduction in RSV-related hospitalizations compared to those born to unvaccinated mothers during peak RSV season. This effectiveness remained consistent across socioeconomic groups and geographic regions, suggesting equitable protection when access is ensured.
These findings align with the Phase III MATISSE trial published in The Latest England Journal of Medicine, which reported an 81.8% efficacy against severe medically attended RSV lower respiratory tract infection in infants through 90 days of life. The UKHSA data extends this evidence into real-world settings, confirming that the vaccine performs as expected outside controlled trial conditions.
“Seeing such a strong real-world effect reinforces that maternal RSV vaccination is not just a clinical trial success—it’s a public health tool that works in diverse populations. The key now is ensuring equitable access so all infants benefit, regardless of where they live or their background.”
Geo-Epidemiological Bridging: Implications for Global Access
In the United Kingdom, the RSVpreF vaccine is recommended by the Joint Committee on Vaccination and Immunisation (JCVI) for use in pregnant women between 28 and 36 weeks gestation, with implementation underway through the National Health Service (NHS) as part of seasonal immunization programs. In the United States, the Centers for Disease Control and Prevention (CDC) recommends maternal RSV vaccination during weeks 32 through 36 of pregnancy, administered seasonally from September to January. The Food and Drug Administration (FDA) approved RSVpreF in August 2023 for this indication.
In the European Union, the European Medicines Agency (EMA) granted marketing authorization for Abrysvo in November 2022 for active immunization of pregnant women to protect infants from birth through six months. However, rollout varies by member state, with some countries integrating it into national immunization schedules while others await further cost-effectiveness analyses.
In low- and middle-income countries, where RSV mortality remains disproportionately high, access is limited by cost and cold-chain requirements. The World Health Organization (WHO) has prioritized RSV vaccine development for global use and is evaluating maternal immunization strategies through its Strategic Advisory Group of Experts (SAGE). Gavi, the Vaccine Alliance, is exploring financing mechanisms to support introduction in eligible countries by 2027, contingent on price reductions and demonstrated health system readiness.
“Maternal RSV vaccination has the potential to prevent tens of thousands of infant hospitalizations globally each year. But to realize this promise, we must address affordability and delivery challenges in resource-limited settings where the burden of RSV is greatest.”
Funding, Transparency, and Independent Validation
The UKHSA study was conducted using publicly funded disease surveillance systems and did not receive direct industry sponsorship. Researchers accessed linked data from the NHS Immunisation Management Service, Hospital Episode Statistics, and death registries under Section 251 of the NHS Act 2006, with approval from the Confidentiality Advisory Group. This minimizes potential conflicts of interest and strengthens the credibility of the observational findings.
The underlying MATISSE trial, which led to regulatory approval, was sponsored by Pfizer. However, the study design, data collection, and analysis were overseen by an independent steering committee, and results were peer-reviewed before publication. Regulatory agencies including the FDA, EMA, and WHO conducted independent assessments of the evidence prior to recommending use.
| Study | Design | Population | Primary Efficacy Outcome | Effectiveness Against Hospitalization |
|---|---|---|---|---|
| MATISSE (NCT04424316) | Phase III, randomized, double-blind, placebo-controlled | 7,358 pregnant women. infants followed to 12 months | 81.8% efficacy against severe RSV-LRTI in infants 0-90 days | Not directly measured (trial focused on medically attended LRTI) |
| UKHSA Real-World Study (2024-2026) | Observational, cohort study using national databases | 450,000+ pregnancies in England | N/A (effectiveness study) | 81% reduction in RSV hospitalization in infants 0-6 months |
Contraindications & When to Consult a Doctor
The RSVpreF vaccine is contraindicated in individuals with a history of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine. Pregnant women experiencing moderate or severe acute illness should defer vaccination until recovery, though mild illness without fever is not a precaution. There is no evidence of risk to the fetus from the vaccine, and animal reproductive studies have shown no adverse effects.
Pregnant individuals should consult their healthcare provider if they have a history of Guillain-Barré syndrome within six weeks of a previous vaccine dose, as a precautionary measure. After vaccination, monitor for signs of allergic reaction such as difficulty breathing, swelling of the face or throat, or widespread rash—though these are extremely rare. Infants do not require direct vaccination; protection is conferred maternally.
If an infant under six months develops persistent cough, wheezing, difficulty breathing, bluish lips or fingertips, or refuses to feed, seek immediate medical attention. These may indicate severe RSV infection requiring hospitalization, even in vaccinated mothers’ infants, as no vaccine offers 100% protection.
Breastfeeding is not a contraindication to maternal RSV vaccination and may provide additional antibody transfer through breast milk, though the primary protective mechanism remains transplacental IgG transfer.
The Path Forward: Expanding Access and Monitoring Long-Term Impact
As maternal RSV vaccination programs scale, ongoing surveillance will be critical to monitor duration of impact, potential effects on viral evolution, and long-term infant health outcomes. Real-world studies like the UKHSA analysis provide essential feedback for optimizing timing, dosage, and delivery strategies. Future research may explore extending maternal vaccination to earlier gestational windows or evaluating the safety and efficacy of co-administration with other prenatal vaccines such as Tdap and influenza.
Equitable access remains the central challenge. While high-income countries are implementing maternal RSV vaccination through public health systems, global equity will require tiered pricing, technology transfer, and sustained investment in cold-chain infrastructure. Until then, the preventable burden of RSV will continue to fall disproportionately on the most vulnerable infants worldwide.
References
- New England Journal of Medicine. Efficacy of Maternal RSV Vaccination in Infants.
- The Lancet. Real-World Effectiveness of Maternal Immunization Against RSV.
- Centers for Disease Control and Prevention. RSV Vaccination Recommendations.
- European Medicines Agency. Abrysvo (RSVpreF) Assessment Report.
- World Health Organization. SAGE Working Group on RSV Vaccines.
